Study Description

The overall study consists of a Screening Period of up to 4 weeks and an Open-Label Treatment Period which will continue until the approval of the marketing application for the Polyarticular-course Juvenile Idiopathic Arthritis (JIA) indication in the study participant's country or region or until further notice from UCB (approximately 4-6 years duration; depending on region). A Final Visit will be conducted 12 weeks after last dose of study medication. Overall, study visits will occur monthly during the first 6 months and every 2 months afterwards. All patients will receive active treatment with Certolizumab Pegol. The dose will depend on actual weight. Home dosing will be allowed between study visits.

If less than 50 % of the study population achieves an adequate response to the treatment (American College of Rheumatology Pediatric 30 % (PedACR30) response) at Week 16, the study will be entirely discontinued.

Condition or Disease	Intervention/Treatment
Polyarticular-course Juvenile Idiopathic Arthritis (JIA)	Drug: Certolizumab Pegol (CZP) Drug: Certolizumab Pegol (CZP)

Study Design

Study Type	Interventional
Actual Enrollment	193 participants
Design Allocation	N/A
Interventional Model	Single Group Assignment
Masking	None (Open Label)
Primary Purpose	Treatment
Official Title	A Multicenter, Open-label Study to Assess the Pharmacokinetics, Safety and Efficacy of Certolizumab Pegol in Children and Adolescents With Moderately to Severely Active Polyarticular-course Juvenile Idiopathic Arthritis (JIA)
Study Start Date	March 8, 2012
Actual Primary Completion Date	April 8, 2024
Actual Study Completion Date	April 8, 2024

Groups and Cohorts

Group/ Cohort

Intervention/ Treatment

Certolizumab Pegol Active treatment with Certolizumab Pegol; dose adjustment is based on weight.

Drug: Certolizumab Pegol (CZP) CZP will be administered subcutaneously as a fixed dose based on weight every 2 weeks (Q2W) or every 4 weeks (Q4W) throughout the study. CZP will be provided by UCB as a CZP 200 mg/ml solution for single subcutaneous (sc) injection, in a single use prefilled syringe (PFS). Each PFS contains an extractable volume of 0.25 mL, 0.5 mL or 1 mL of CZP solution. Eligible subjects will begin with 3 loading doses of CZP followed by a treatment dose for the duration of the study based on the weight range. Reduced CZP regimen (after implementation of protocol amendments 4 and 5): 10 to < 20 kg: Loading dose = 50 mg Q2W (1 x 0.25 mL sc); treatment dose = 50 mg Q4W (1 x 0.25 mL sc); 20 to < 40 kg: Loading dose = 100 mg Q2W (1 x 0.5 mL sc,); treatment dose = 50 mg Q2W (1 x 0.25 mL sc); ≥ 40 kg: Loading dose = 200 mg Q2W (1 x 1.0 mL sc); treatment dose = 100 mg Q2W (1 x 0.5 mL sc);

Outcome Measures

Primary Outcome Measures

1. Certolizumab Pegol (CZP) Plasma Concentration Level at Week 16 [Week 16]
   Certolizumab Pegol (CZP) plasma concentration level was measured in micrograms per milliliter (ug/ml).
2. Certolizumab Pegol (CZP) Plasma Concentration Level at Week 48 [Week 48]
   Certolizumab Pegol (CZP) plasma concentration level was measured in ug/mL.
3. Number of Participants With Anti-Certolizumab Pegol (Anti-CZP) Antibody Level at Week 16 [Week 16]
   Number of participants with anti-CZP antibodies were reported.
4. Number of Participants With Anti-Certolizumab Pegol (Anti-CZP) Antibody Level at Week 48 [Week 48]
   Number of participants with anti-CZP antibodies were reported.
5. Number of Participants With Serious Treatment-emergent Adverse Events (TEAEs) During the Study [From Baseline (Week 0) up to the Final Visit (70 days after final dose of CZP) (maximum up to 12 years)]
   A Serious Adverse Event (SAE) is any untoward medical occurrence that at any dose: results in deaths, is life-threatening, requires in patient hospitalization or prolongation of existing hospitalization, is a congenital anomaly or birth defect and other important medical events which based on medical or scientific judgement may jeopardize the patients, or may require medical or surgical intervention to prevent any of the above. TEAEs are defined as AEs starting on or after first administration of CZP and up to 70 days after last dose of study medication.
6. Number of Participants With Treatment-emergent Adverse Events (TEAEs) Leading to Permanent Withdrawal of the Investigational Medicinal Product (IMP) During the Study [From Baseline (Week 0) up to the Final Visit (70 days after final dose of CZP) (maximum up to 12 years)]
   An AE is any untoward medical occurrence in a patient or clinical investigation study participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of an IMP, whether or not related to the IMP. TEAEs are defined as AEs starting on or after first administration of CZP and up to 70 days after last dose of study medication. TEAEs leading to permanent withdrawal of the IMP during the study were reported in this outcome measure.

Secondary Outcome Measures

1. Percentage of Participants Meeting American College of Rheumatology Pediatric 30 % (PedACR30) Response Criteria at Week 16 [Week 16]
   PedACR30-at least 30% improvement from baseline in 3 of any 6 core set measures, with no more than 1 of remaining variables worsening by >30%:
   
   Number of joints with active arthritis
   
   Number of joints with limitation of range of motion
   
   Physician's Global Assessment of Disease Activity (using visual analog scale (VAS): 100mm; 0= very good, and 100= very poor)
   
   CHAQ (30 questions, 8 domains, scores for each domain are averaged to calculate total score [ 0= no disability to 3= very severe disability])
   
   Parent's Global Assessment of Overall Well-Being (using VAS: 100mm; 0= Very well to 100= Very poor)
   
   C-reactive protein (CRP)
2. Percentage of Participants Meeting American College of Rheumatology Pediatric 50 % (PedACR50) Response Criteria at Week 16 [Week 16]
   PedACR50- at least 50% improvement from baseline in 3 of any 6 core set measures, with no more than 1 of remaining variables worsening by >30%:
   
   Number of joints with active arthritis
   
   Number of joints with limitation of range of motion
   
   Physician's Global Assessment (PGA) of Disease Activity (using VAS: 100mm; 0= very good, and 100= very poor)
   
   Childhood Health Assessment Questionnaire (CHAQ) (30 questions, 8 domains, scores for each domain are averaged to calculate total score [ 0= no disability to 3= very severe disability])
   
   Parent's Global Assessment of Overall Well-Being (using VAS: 100mm; 0= Very well to 100= Very poor)
   
   CRP
3. Percentage of Participants Meeting American College of Rheumatology Pediatric 70 % (PedACR70) Response Criteria at Week 16 [Week 16]
   PedACR70- at least 70% improvement from baseline in 3 of any 6 following core set measures, with no more than 1 of remaining variables worsening by >30%:
   
   Number of joints with active arthritis
   
   Number of joints with limitation of range of motion
   
   Physician's Global Assessment of Disease Activity (using VAS: 100mm; 0= very good, and 100= very poor)
   
   CHAQ (30 questions, 8 domains, scores for each domain are averaged to calculate total score [ 0= no disability to 3= very severe disability])
   
   Parent's Global Assessment of Overall Well-Being (using VAS: 100mm; 0= Very well to 100= Very poor)
   
   CRP
4. Percentage of Participants Meeting American College of Rheumatology Pediatric 90 % (PedACR90) Response Criteria at Week 16 [Week 16]
   PedACR90- at least 90% improvement from baseline in 3 of any 6 following core set measures, with no more than 1 of remaining variables worsening by >30%:
   
   Number of joints with active arthritis
   
   Number of joints with limitation of range of motion
   
   Physician's Global Assessment of Disease Activity (using VAS: 100mm; 0= very good, and 100= very poor)
   
   CHAQ (30 questions, 8 domains, scores for each domain are averaged to calculate total score [ 0= no disability to 3= very severe disability])
   
   Parent's Global Assessment of Overall Well-Being (using VAS: 100mm; 0= Very well to 100= Very poor)
   
   CRP

Eligibility Criteria

Ages Eligible for Study	2 Years to 17 Years (Child)
Sexes Eligible for Study	All
Accepts Healthy Volunteers	No
Inclusion Criteria	Study participant is 2 to 17 years of age (inclusive) at Baseline (Visit 2) Study participants must weigh ≥10 kg (22lb) at Baseline (Visit 2) Study participants must have had onset of signs and symptoms consistent with a diagnosis of Juvenile Idiopathic Arthritis (JIA) (according to the International League of Associations for Rheumatology Classification of Juvenile Idiopathic Arthritis, 2001) and initiation of JIA treatment for at least 6 months prior to Baseline (Visit 2). Eligible JIA categories include: polyarthritis rheumatoid factor-positive, polyarthritis rheumatoid factor-negative, extended oligoarthritis, juvenile psoriatic arthritis, and enthesitis-related arthritis (ERA) Study participants must have active polyarticular-course disease, defined as ≥5 joints with active arthritis at Screening and at Baseline Study participants must have had an inadequate response to, or intolerance to, at least 1 disease-modifying antirheumatic drug (DMARD) (nonbiologic or biologic). For example, study participant had prior inadequate response to methotrexate (MTX) (based on the Investigator's clinical judgment) If the study participant is using MTX, then the study participant must have been on MTX for a minimum of 3 months at Screening. In addition, the dose must have been stable for at least 1 month before Screening at ≥10 to ≤15 mg/m^2 per week. If the study participant is not using MTX, then the treatment must have been previously withdrawn for documented reasons of intolerability or inadequate response If the study participant is using oral corticosteroid therapy, the dose must have been stable for at least 7 days prior to the Baseline arthritis assessment at a maximum dose of 10 mg or 0.2 mg/kg prednisone (or equivalent) per day, whichever is the smaller dose
Exclusion Criteria	Study participant has previously been exposed to more than 2 biologic agents Study participant previously failed to respond to treatment with more than one tumor necrosis factor alpha (TNFα) antagonist drug Study participant is currently receiving or has received any experimental (biological or nonbiological) therapy (within or outside a clinical study) in the 3 months or 5 half-lives prior to Baseline (Visit 2), whichever is longer Study participant had previous treatment with a biological therapy for juvenile idiopathic arthritis (JIA) that resulted in a severe hypersensitivity reaction or an anaphylactic reaction Study participant previously participated in this study or has previously been treated with CZP (whether in a study or not) Study participant has a history of systemic JIA, with or without systemic features Study participant has a secondary, noninflammatory type of rheumatic disease or of joint pains (eg, fibromyalgia) that in the Investigator's opinion is symptomatic enough to interfere with evaluation of the effect of study medication Study participant has other inflammatory arthritis (eg, systemic lupus erythematosus, inflammatory bowel disease-related) Study participant has active uveitis or a history of active uveitis within the preceding 6 months Study participant has current, chronic or recurrent clinically significant infections Study participant has a current sign or symptom which may indicate infection (eg, fever, cough), a history of chronic or recurrent infections within the same organ system (more than 3 episodes requiring antibiotics/antivirals during the 12 months prior to Screening [Visit 1]), had a recent (within the 6 months prior to Screening [Visit 1]) serious or life-threatening infection (including herpes zoster), or is at a high risk of infection in the Investigator's opinion (eg, study participants with leg ulcers, indwelling urinary catheter, and persistent or recurrent chest infections or permanently bed-ridden or wheelchair bound)

Contacts and Locations

Sponsors and Collaborators	UCB BIOSCIENCES GmbH, PRA Health Sciences
	PRA Health Sciences
Locations	Ra0043 71 | Little Rock, Arkansas, United States, 72202 Ra0043 79 | Los Angeles, California, United States, 90027-6062 Ra0043 84 | San Francisco, California, United States, 94143 Ra0043 83 | Hartford, Connecticut, United States, 06106 Ra0043 81 | Washington, District of Columbia, United States, 20010 Ra0043 82 | Chicago, Illinois, United States, 60611 Ra0043 90 | Chicago, Illinois, United States, 60637 Ra0043 75 | Indianapolis, Indiana, United States, 46202 Ra0043 80 | Hackensack, New Jersey, United States, 07601 Ra0043 77 | Livingston, New Jersey, United States, 07039 Ra0043 85 | New Hyde Park, New York, United States, 11042 Ra0043 87 | New York, New York, United States, 10032 Ra0043 74 | Charlotte, North Carolina, United States, 28203 Ra0043 76 | Durham, North Carolina, United States, 27710 Ra0043 70 | Avon, Ohio, United States, 44011 Ra0043 73 | Cincinnati, Ohio, United States, 45229 Ra0043 78 | Cleveland, Ohio, United States, 44109 Ra0043 95 | Cleveland, Ohio, United States, 44195 Ra0043 86 | Columbus, Ohio, United States, 43205-2694 Ra0043 89 | Portland, Oregon, United States, 97227 RA0043 2 | Buenos Aires, Argentina, Ra0043 15 | Curitiba, Brazil, Ra0043 14 | Porto Alegre, Brazil, Ra0043 12 | Sao Paulo, Brazil, Ra0043 21 | Calgary, Canada, Ra0043 22 | Montreal, Canada, Ra0043 20 | Toronto, Canada, Ra0043 60 | Santiago, Chile, Ra0043 32 | Mexico D.F., Mexico, Ra0043 31 | Mexico, Mexico, Ra0043 30 | Monterrey, Mexico, Ra0043 33 | San Luis Potosi, Mexico, Ra0043 41 | Moscow, Russian Federation, Ra0043 43 | Moscow, Russian Federation, Ra0043 40 | St. Petersburg, Russian Federation, Ra0043 42 | Tolyatti, Russian Federation,
Investigators

Study Documents (Full Text)

• Documents Provided by UCB BIOSCIENCES GmbH: Study Protocol April 27, 2020
• Documents Provided by UCB BIOSCIENCES GmbH: Statistical Analysis Plan May 23, 2024

More Information

Additional Relevant MeSH Terms

• Arthritis
• Arthritis, Juvenile
• Joint Diseases
• Musculoskeletal Diseases
• Rheumatic Diseases
• Connective Tissue Diseases
• Autoimmune Diseases
• Immune System Diseases